S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Senate parliamentarian OKs most of Dems' drug price controls
Dems' climate, energy, tax bill clears initial Senate hurdle
Senate rules referee weakens Dem drug plan in economic bill
Demand for grocery delivery cools as food costs rise
Venezuela, Colombia border areas hopeful as reopening looms
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Senate parliamentarian OKs most of Dems' drug price controls
Dems' climate, energy, tax bill clears initial Senate hurdle
Senate rules referee weakens Dem drug plan in economic bill
Demand for grocery delivery cools as food costs rise
Venezuela, Colombia border areas hopeful as reopening looms
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Senate parliamentarian OKs most of Dems' drug price controls
Dems' climate, energy, tax bill clears initial Senate hurdle
Senate rules referee weakens Dem drug plan in economic bill
Demand for grocery delivery cools as food costs rise
Venezuela, Colombia border areas hopeful as reopening looms
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Senate parliamentarian OKs most of Dems' drug price controls
Dems' climate, energy, tax bill clears initial Senate hurdle
Senate rules referee weakens Dem drug plan in economic bill
Demand for grocery delivery cools as food costs rise
Venezuela, Colombia border areas hopeful as reopening looms
NYSE:MCK

McKesson (MCK) Stock Forecast, Price & News

$346.69
+8.88 (+2.63%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$336.62
$346.98
50-Day Range
$300.57
$346.69
52-Week Range
$192.38
$348.49
Volume
1.17 million shs
Average Volume
897,871 shs
Market Capitalization
$49.78 billion
P/E Ratio
36.65
Dividend Yield
0.54%
Price Target
$332.85

McKesson MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
4.0% Downside
$332.85 Price Target
Short Interest
Healthy
1.74% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.01
Upright™ Environmental Score
News Sentiment
0.41mentions of McKesson in the last 14 days
Based on 37 Articles This Week
Insider Trading
Selling Shares
$23.78 M Sold Last Quarter
Proj. Earnings Growth
4.93%
From $24.33 to $25.53 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

102nd out of 1,283 stocks

Drugs, Proprietaries, & Sundries Industry

3rd out of 8 stocks

McKesson logo

About McKesson (NYSE:MCK) Stock

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Wall Street Analyst Weigh In

A number of research analysts recently commented on MCK shares. Argus cut McKesson from a "buy" rating to a "hold" rating in a report on Wednesday, July 6th. UBS Group lifted their price objective on McKesson from $380.00 to $400.00 and gave the stock a "buy" rating in a research note on Thursday. Credit Suisse Group lifted their price objective on McKesson from $333.00 to $377.00 in a research note on Wednesday, May 11th. Deutsche Bank Aktiengesellschaft raised McKesson from a "hold" rating to a "buy" rating and boosted their target price for the company from $343.00 to $378.00 in a research report on Tuesday, June 7th. Finally, Cowen boosted their target price on McKesson from $325.00 to $361.00 and gave the company an "outperform" rating in a research report on Monday, April 18th. Two investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $332.85.

McKesson Stock Up 2.6 %

Shares of McKesson stock opened at $346.69 on Friday. The stock's fifty day moving average is $324.08 and its two-hundred day moving average is $306.51. The company has a market capitalization of $49.78 billion, a PE ratio of 36.65, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63. McKesson has a 52 week low of $192.38 and a 52 week high of $348.49.

McKesson (NYSE:MCK - Get Rating) last announced its quarterly earnings data on Thursday, May 5th. The company reported $5.83 EPS for the quarter, missing the consensus estimate of $6.06 by ($0.23). The business had revenue of $66.10 billion during the quarter, compared to the consensus estimate of $63.82 billion. McKesson had a net margin of 0.52% and a negative return on equity of 350.22%. The business's revenue was up 11.8% compared to the same quarter last year. During the same period last year, the company earned $5.05 EPS. As a group, research analysts anticipate that McKesson will post 23.27 earnings per share for the current year.

McKesson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, October 3rd. Shareholders of record on Thursday, September 1st will be issued a $0.54 dividend. This represents a $2.16 annualized dividend and a dividend yield of 0.62%. This is a boost from McKesson's previous quarterly dividend of $0.47. The ex-dividend date of this dividend is Wednesday, August 31st. McKesson's dividend payout ratio is currently 19.87%.

Insiders Place Their Bets

In other McKesson news, CEO Brian S. Tyler sold 5,438 shares of the company's stock in a transaction on Monday, May 9th. The stock was sold at an average price of $330.93, for a total value of $1,799,597.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other McKesson news, EVP Thomas L. Rodgers sold 160 shares of the company's stock in a transaction on Monday, June 6th. The stock was sold at an average price of $316.42, for a total value of $50,627.20. Following the completion of the sale, the executive vice president now directly owns 3,844 shares in the company, valued at approximately $1,216,318.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Brian S. Tyler sold 5,438 shares of the company's stock in a transaction on Monday, May 9th. The stock was sold at an average price of $330.93, for a total value of $1,799,597.34. The disclosure for this sale can be found here. In the last ninety days, insiders sold 72,628 shares of company stock worth $23,779,745. 0.21% of the stock is currently owned by company insiders.

Receive MCK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for McKesson and its competitors with MarketBeat's FREE daily newsletter.

MCK Stock News Headlines

States reach deal over marketing, safety of generic opioids
A former opioid manufacturer is agreeing in principle to pay up to $2.4 billion in a deal with a dozen states over its marketing and product safety practices
West Virginia officials to appeal opioid lawsuit decision
Officials in a West Virginia county plan to appeal a federal judge’s ruling in favor of three major U.S. drug distributors in a landmark lawsuit that accused them of causing a health crisis by distributing 81 million pills over eight years
What 6 Analyst Ratings Have To Say About McKesson
McKesson (MCK) Tops Q1 Earnings and Revenue Estimates
McKesson (MCK) to Release Earnings on Wednesday
See More Headlines

Receive MCK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for McKesson and its competitors with MarketBeat's FREE daily newsletter.

MCK Company Calendar

Last Earnings
10/31/2021
Ex-Dividend for 7/1 Dividend
5/31/2022
Dividend Payable
7/01/2022
Today
8/07/2022
Ex-Dividend for 10/3 Dividend
8/31/2022
Dividend Payable
10/03/2022
Next Earnings (Estimated)
11/07/2022
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Drugs, proprietaries, & sundries
Sub-Industry
Health Care Distributors
Sector
Medical
CUSIP
58155Q10
Employees
75,000
Year Founded
1833

Price Target and Rating

Average Stock Price Forecast
$332.85
High Stock Price Forecast
$400.00
Low Stock Price Forecast
$230.00
Forecasted Upside/Downside
-4.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$1.11 billion
Pretax Margin
0.88%

Debt

Sales & Book Value

Annual Sales
$263.97 billion
Cash Flow
$31.55 per share
Book Value
($10.25) per share

Miscellaneous

Free Float
143,279,000
Market Cap
$49.78 billion
Optionable
Optionable
Beta
0.63

Social Links















MCK Stock - Frequently Asked Questions

Should I buy or sell McKesson stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" McKesson stock.
View analyst ratings for McKesson
or view top-rated stocks.

What is McKesson's stock price forecast for 2022?

12 Wall Street analysts have issued twelve-month target prices for McKesson's stock. Their MCK stock forecasts range from $230.00 to $400.00. On average, they expect McKesson's stock price to reach $332.85 in the next year. This suggests that the stock has a possible downside of 4.0%.
View analysts' price targets for McKesson
or view top-rated stocks among Wall Street analysts.

How has McKesson's stock performed in 2022?

McKesson's stock was trading at $248.57 at the start of the year. Since then, MCK stock has increased by 39.5% and is now trading at $346.69.
View the best growth stocks for 2022 here
.

When is McKesson's next earnings date?

McKesson is scheduled to release its next quarterly earnings announcement on Monday, November 7th 2022.
View our earnings forecast for McKesson
.

How were McKesson's earnings last quarter?

McKesson Co. (NYSE:MCK) announced its quarterly earnings results on Sunday, October, 31st. The company reported $6.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.66 by $1.49. The business had revenue of $66.58 billion for the quarter, compared to the consensus estimate of $63.23 billion. McKesson had a net margin of 0.52% and a negative trailing twelve-month return on equity of 350.22%. McKesson's revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the previous year, the company earned $4.80 EPS.
Read McKesson's conference call transcript
.

How often does McKesson pay dividends? What is the dividend yield for McKesson?

McKesson declared a quarterly dividend on Monday, July 25th. Investors of record on Thursday, September 1st will be given a dividend of $0.54 per share on Monday, October 3rd. This represents a $2.16 annualized dividend and a yield of 0.62%. The ex-dividend date is Wednesday, August 31st. This is an increase from McKesson's previous quarterly dividend of $0.47.
View McKesson's dividend history
.

Is McKesson a good dividend stock?

McKesson(NYSE:MCK) pays an annual dividend of $1.88 per share and currently has a dividend yield of 0.54%. McKesson has been increasing its dividend for 16 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of McKesson is 19.87%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, McKesson will have a dividend payout ratio of 7.36% next year. This indicates that McKesson will be able to sustain or increase its dividend.
View McKesson's dividend history.

How will McKesson's stock buyback program work?

McKesson declared that its Board of Directors has initiated a stock repurchase program on Tuesday, February 2nd 2021, which authorizes the company to repurchase $2,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 6.9% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's board of directors believes its stock is undervalued.

What guidance has McKesson issued on next quarter's earnings?

McKesson issued an update on its FY23 earnings guidance on Wednesday, August, 3rd. The company provided earnings per share (EPS) guidance of $23.95-24.65 for the period, compared to the consensus EPS estimate of $23.33.

What is Brian Tyler's approval rating as McKesson's CEO?

220 employees have rated McKesson CEO Brian Tyler on Glassdoor.com. Brian Tyler has an approval rating of 88% among McKesson's employees.

What other stocks do shareholders of McKesson own?

Based on aggregate information from My MarketBeat watchlists, some companies that other McKesson investors own include Walt Disney (DIS), Johnson & Johnson (JNJ), Gilead Sciences (GILD), CVS Health (CVS), AbbVie (ABBV), Bank of America (BAC), AT&T (T), JPMorgan Chase & Co. (JPM), UnitedHealth Group (UNH) and Home Depot (HD).

What is McKesson's stock symbol?

McKesson trades on the New York Stock Exchange (NYSE) under the ticker symbol "MCK."

Who are McKesson's major shareholders?

McKesson's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Pzena Investment Management LLC (1.69%), Scharf Investments LLC (0.49%), Robeco Institutional Asset Management B.V. (0.47%), Sumitomo Mitsui Trust Holdings Inc. (0.30%), Russell Investments Group Ltd. (0.29%) and Border to Coast Pensions Partnership Ltd (0.28%). Company insiders that own McKesson stock include Brian S Tyler, Brian S Tyler, Britt J Vitalone, Kevin Emerson, Lori A Schechter, Lori A Schechter, Marie L/Ca Knowles, Nancy Flores, Sundeep G Reddy, Sundeep G Reddy, Thomas L Rodgers, Thomas L Rodgers and Tracy Faber.
View institutional ownership trends for McKesson
.

How do I buy shares of McKesson?

Shares of MCK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is McKesson's stock price today?

One share of MCK stock can currently be purchased for approximately $346.69.

How much money does McKesson make?

McKesson (NYSE:MCK) has a market capitalization of $49.78 billion and generates $263.97 billion in revenue each year. The company earns $1.11 billion in net income (profit) each year or $9.46 on an earnings per share basis.

How many employees does McKesson have?

McKesson employs 75,000 workers across the globe.

Does McKesson have any subsidiaries?

The following companies are subsidiares of McKesson: A.L.I. Technologies, AMISYS Managed Care Systems, Abaton.com, Access Health, Biologics, Celesio, CoverMyMeds, D & K Healthcare Resources, Drug Trading Co. Ltd., EN-Chart Scanning Program, Echo, Emendo, Enterprise Systems Inc., HBO & Company, HPR, HealthCom Partners, HealthQx, IMNET Systems, LloydsDirect, MED3000, McKesson Europe AG, McKesson Europe Holdings GmbH & Co. KGaA, McKesson Global Procurement & Sourcing Limited, McKesson International Bermuda IP2A Limited, McKesson International Bermuda IP3A Limited, McKesson Ireland Limited, McKesson Medical-Surgical Holdings Inc., McKesson Medical-Surgical Inc., McKesson Medical-Surgical Supply Chain Services LLP, McKesson Medical-Surgical Top Holdings Inc., McKesson Plasma and Biologics LLC, McKesson Specialty Care Distribution LLC, McKesson UK Finance I Limited, McKesson UK Finance II Limited, McKesson US Finance Corporation, McQueary Brothers, MedVentive, Medcon, MediVation Inc., Medical Specialties Distributors, Medis Health And Pharmaceutical Services, Moore Medical, NDCHealth, Oncology Therapeutics Network, PSS World Medical, Per-Se Technologies, Portico Systems, Practice Partner, RedLine HealthCare, RelayHealth, Rexall, Rosebud Solutions, RxCrossroads, Sterling Medical Services LLC, UDG Healthcare, US Oncology, US Oncology Holdings Inc., US Oncology Inc., United Drug (Wholesale) Limited, United Drug Distributors Ireland Limited, Vantage Oncology, Vivalog Technologies, Well.ca, and peerVue.
Read More

When was McKesson founded?

McKesson was founded in 1833.

How can I contact McKesson?

McKesson's mailing address is 6555 STATE HWY 161, IRVING TX, 75039. The official website for McKesson is www.mckesson.com. The company can be reached via phone at (972) 446-4800, via email at investors@mckesson.com, or via fax at 415-983-8453.

This page (NYSE:MCK) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.